%PDF-1.4
%
29 0 obj
<>
endobj
26 0 obj
<>
endobj
86 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2005-02-28T18:54:15Z
2024-03-28T08:58:40-07:00
QuarkXPressª: AdobePS 8.8.0 (301)
2024-03-28T08:58:40-07:00
application/pdf
Heather
2005-33.april
uuid:55fc9be0-1dd2-11b2-0a00-db08271d5700
uuid:55fc9be3-1dd2-11b2-0a00-bf0000000000
endstream
endobj
15 0 obj
<>
endobj
16 0 obj
<>
endobj
30 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 7 0 R/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 9 0 R/Type/Page>>
endobj
92 0 obj
[96 0 R]
endobj
93 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
13.5 787.5 585 -783 re
W n
q
0 792.03 612 -792 re
W n
BT
0 0 0 1 k
/GS1 gs
/T1_0 1 Tf
-0.0101 Tc 0.0777 Tw 10 0 0 10 54 734.8264 Tm
(new technology the most promising application seems to be)Tj
0.0081 Tw 0 -1.2 TD
(the use of proteomics \(the analysis of protein-expression pro-)Tj
-0.0289 Tw T*
(files\), utilizing gel and non-gel based mass spectrometry tech-)Tj
0.1646 Tw T*
[(niques. Non-gel based techniques include SELDI-T)17.9 (OF-MS)]TJ
0.2285 Tw T*
(\(surface-enhanced laser desorption/ionization time-of-flight)Tj
0.07201 Tw T*
(mass spectrometry\). Gel based approaches include 2-dimen-)Tj
0.1841 Tw T*
(sional gel electrophoresis coupled to MALDI-MS \(matrix-)Tj
0.02499 Tw T*
(assisted laser desorption/ionization mass spectrometry\))Tj
0 Tc 0 Tw 7.5 0 0 7.5 269.9743 654.1265 Tm
(9)Tj
10 0 0 10 273.6493 650.8264 Tm
(.)Tj
-0.00011 Tc 0.0957 Tw -20.7649 -1.2 Td
(The new proteomics technology has recently been used)Tj
0.12151 Tw -1.2 -1.2 Td
(to screen for patterns of putative biomarkers in the serum)Tj
0.0575 Tw T*
[(that might be related to disease etiology)64.8 (, without a specific)]TJ
0.03529 Tw T*
[(candidate protein\(s\) or glycoprotein\(s\). )54.8 (Another application)]TJ
0.0323 Tw T*
(is in the decision-making process with respect to treatment,)Tj
0.168 Tw T*
(when there is believed to be heterogeneity of therapeutic)Tj
0.07159 Tw T*
[(ef)17.7 (ficacy)64.8 (. )17.7 (The paradigm of prescribing celecoxib to patients)]TJ
0.1259 Tw T*
(with familial adenomatous polyposis is instructive. Serum)Tj
0.2617 Tw T*
[(proteomic profiles in these patients dif)17.7 (fer depending on)]TJ
0.08479 Tw T*
(whether they are responsive or nonresponsive to celecoxib)Tj
0.13989 Tw T*
(\(reduction in both the number and size of gastrointestinal)Tj
0 Tw T*
(polyps\))Tj
0 Tc 7.5 0 0 7.5 83.9951 510.1265 Tm
(10)Tj
-0.00011 Tc 0.03439 Tw 10 0 0 10 91.4951 506.8264 Tm
[(. )17.8 (Thus, the technology could be used in risk-bene-)]TJ
0.0105 Tw -3.7495 -1.2 Td
(fit analysis with respect to an estimate of the cardiovascular)Tj
0.02499 Tw T*
(risk for this drug)Tj
-0.04919 Tc 0 Tw 7.5 0 0 7.5 121.6739 486.1265 Tm
(11)Tj
0 Tc 10 0 0 10 128.8052 482.8264 Tm
(.)Tj
-0.00011 Tc 0.0107 Tw -6.2805 -1.2 Td
(But will advances in biomarker technology lead to better)Tj
0.2925 Tw -1.2 -1.2 Td
(insight in the pathogenesis and drug treatment of OA?)Tj
0.06351 Tw T*
[(Historically)64.8 (, human OA)-258.7 (has been thought to be primarily a)]TJ
0.0184 Tw T*
(remodeling process of bone, in the subchondral regions and)Tj
0.1633 Tw T*
[(at the mar)17.7 (gins of the joint, as had been comprehensively)]TJ
0.0002 Tc 0.37469 Tw T*
[(described by Leon Sokolof)17.7 (f)]TJ
0 Tw 7.5 0 0 7.5 176.478 414.1265 Tm
(12)Tj
0.37469 Tw 10 0 0 10 190.2317 410.8264 Tm
(and previously by Lent)Tj
0 Tc 0 Tw -13.6232 -1.2 Td
(Johnson)Tj
7.5 0 0 7.5 86.7783 402.1265 Tm
(13)Tj
-0.00011 Tc 0.1776 Tw 10 0 0 10 94.2783 398.8264 Tm
(. On the other hand, the Pond-Nuki dog model)Tj
0.22 Tw -4.0278 -1.2 Td
(\(anterior cruciate ligament section\) had provided a great)Tj
0.022 Tw T*
[(deal of impetus for experimentalists to regard OA)-217.3 (primarily)]TJ
0.04179 Tw T*
[(as a disease of articular cartilage. )17.7 (Thus, it is hardly surpris-)]TJ
0.14529 Tw T*
(ing that if a drug was originally developed around a bio-)Tj
0.05881 Tw T*
[(chemical tar)17.7 (get located in either cartilage or bone, then the)]TJ
0.0287 Tw T*
(endpoints and the markers in the clinical trials for that drug)Tj
0.19279 Tw T*
[(would also be designed to reflect that tar)17.7 (get. Diacerein)]TJ
0 Tc 0 Tw 7.5 0 0 7.5 287.75 318.1265 Tm
(3)Tj
10 0 0 10 291.5 314.8264 Tm
(,)Tj
-0.00011 Tc 0.0226 Tw -23.75 -1.2 Td
(which was initially developed as an interleukin 1 and colla-)Tj
0.06039 Tw T*
(genase inhibitor in articular cartilage, is an interesting case)Tj
0.13049 Tw T*
(in point, as there is now a significant literature indicating)Tj
0.02499 Tw T*
[(that it may have ef)17.7 (fects on both cartilage and bone.)]TJ
0.0506 Tw 1.2 -1.2 Td
[(Further)39.7 (, even drugs that are thought to be bone-specific,)]TJ
0.0463 Tw -1.2 -1.2 Td
(such as the diphosphonates, can be observed in experimen-)Tj
0.05991 Tw T*
(tal models to repair articular cartilage)Tj
0 Tc 0 Tw 7.5 0 0 7.5 207.188 234.1265 Tm
(14)Tj
-0.00011 Tc 0.06 Tw 10 0 0 10 214.688 230.8264 Tm
(. It is now apparent)Tj
0.0704 Tw -16.0688 -1.2 Td
(that older pathological work on subchondral bone needs to)Tj
-0.03239 Tw T*
(be revisited in view of the prominence recently given to sub-)Tj
0.2561 Tw T*
(chondral bone lesions, identified by magnetic resonance)Tj
0.1156 Tw T*
(imaging, that probably develop as a result of biomechani-)Tj
0.0611 Tw T*
(cally induced bone resorption)Tj
0 Tc 0 Tw 7.5 0 0 7.5 174.4 174.1265 Tm
(15)Tj
-0.00011 Tc 0.0611 Tw 10 0 0 10 181.9 170.8264 Tm
[(. )54.8 (A)-256.2 (decreased prevalence of)]TJ
0.0719 Tw -12.79 -1.2 Td
[(these subchondral lesions in knee OA)-267.1 (has been reported in)]TJ
0.05 Tw T*
(elderly women treated with alendronate and estrogen and a)Tj
0.02161 Tw T*
(reduction of symptoms in those treated with the diphospho-)Tj
-0.0002 Tc 0 Tw T*
(nate)Tj
0 Tc 7.5 0 0 7.5 70.6553 126.1265 Tm
(16)Tj
-0.00011 Tc 0.1449 Tw 10 0 0 10 78.1553 122.8264 Tm
[(. )17.7 (Thus, the siren song of newer technology for bio-)]TJ
0.13361 Tw -2.4155 -1.2 Td
(chemical markers must not seduce us from going back to)Tj
0.12421 Tw T*
(reevaluate the still poorly understood relationship of bone)Tj
0.16991 Tw 26.4 63.6 Td
[(remodeling to cartilage damage and, potentially)64.8 (, cartilage)]TJ
0.02499 Tw T*
[(repair)39.7 (, as well as the cause of symptoms.)]TJ
/T1_1 1 Tf
-0.0298 Tw 1.6 -2.4 Td
[(T)73.9 (ASSOS ANAST)73.9 (ASSIADES,)]TJ
/T1_0 1 Tf
0 Tc 0.0249 Tw 6 0 0 6 461.0967 698.8264 Tm
(MD, PhD, FRCPC,)Tj
-0.00011 Tc 8 0 0 8 334 688.8264 Tm
[(Professor of Medicine \(Rheumatology\) and Biochemistry)64.9 (,)]TJ
0 -1.25 TD
[(Queen\325)54.8 (s University;)]TJ
/T1_1 1 Tf
10 0 0 10 334 666.8264 Tm
[(KAREN REES-MIL)91.7 (T)17.7 (ON,)]TJ
/T1_0 1 Tf
0 Tw 6 0 0 6 448.1206 666.8264 Tm
(PhD,)Tj
0.0072 Tw 8 0 0 8 334 656.8264 Tm
[(Research )54.9 (Associate, Connective )17.7 (T)35 (issue Laboratories \(Rheumatology\),)]TJ
0.02499 Tw T*
[(Queen\325)54.8 (s University)64.8 (, Kingston, Ontario, Canada.)]TJ
/T1_2 1 Tf
0.0692 Tw -2 -2.5 Td
[(Addr)36.8 (ess r)36.8 (eprint r)36.8 (equests to Dr)110.7 (. T)73.9 (.)-0.1 ( )17.8 (Anastassiades, Etherington Hall, Stuart)]TJ
0.02499 Tw T*
[(Str)36.8 (eet, Kingston, Ontario K7L)-257.3 (3N6. E-mail: anastass@post.queensu.ca)]TJ
/T1_1 1 Tf
0 Tw 10 0 0 10 318 592.8264 Tm
(REFERENCES)Tj
/T1_0 1 Tf
0.02499 Tw 8 0 0 8 325 583.1264 Tm
[(1.)-875.1 (Sharif M, Kirwan JR, Elson CJ, et al. Suggestion of nonlinear or)]TJ
1.675 -1.2125 Td
(phasic progression of knee osteoarthritis based on measurements of)Tj
0 -1.2125 TD
(serum cartilage oligomeric matrix protein levels over five years.)Tj
T*
(Arthritis Rheum 2004;50:2479-88.)Tj
-1.675 -1.2125 Td
[(2.)-875.1 (Otterness IG, Swindell )54.8 (AC, Zimmerer RO, et al. )54.8 (An analysis of 14)]TJ
1.675 -1.2125 Td
(molecular markers for monitoring osteoarthritis: segregation of the)Tj
T*
(markers into clusters and distinguishing osteoarthritis at baseline.)Tj
T*
(Osteoarthritis Cartilage 2000;8:180-5.)Tj
-1.675 -1.2 Td
[(3.)-875.1 (Garnero P)110.7 (, Mazieres BM, Gueguen )54.8 (A, et al. Cross-sectional)]TJ
1.675 -1.2 Td
(association of 10 molecular markers of bone, cartilage, and)Tj
0 -1.2 TD
(synovium with disease activity and radiological joint damage in)Tj
T*
(patients with hip osteoarthritis: the ECHODIAH cohort. )Tj
T*
(J Rheumatol 2005;32:697-703.)Tj
-1.675 -1.2 Td
[(4.)-875.1 (Garnero P)110.7 (,)-0.1 ( Sornay Rendu E, )54.8 (Arlot ME, et al. )54.8 (Association between)]TJ
1.675 -1.2 Td
(spine disc degeneration and type II collagen degradation in post-)Tj
T*
[(menopausal women: )17.7 (The OFEL)99.8 (Y)-238.2 (Study)64.8 (. )54.8 (Arthritis Rheum)]TJ
0 Tc 0 Tw T*
(2004;50:3137-44.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.225 Td
[(5.)-875.1 (Reijman M, Hazes JM, Bierma-Zeinstra SM, et al. )54.8 (A)-220.1 (new marker)]TJ
1.675 -1.225 Td
(for osteoarthritis: cross-sectional and longitudinal approach.)Tj
0 -1.225 TD
(Arthritis Rheum 2004;50:2471-8)Tj
-1.675 -1.225 Td
[(6.)-875.1 (Hopman )17.7 (WM, Ber)17.7 (ger C, Joseph L, et al. Stability of normative data)]TJ
1.675 -1.225 Td
(for the SF-36: results of a three-year prospective study in middle-)Tj
T*
(aged Canadians. Can J Public Health 2004;95:387-91.)Tj
-1.675 -1.225 Td
[(7.)-875.1 (Stef)17.7 (fey MA, Miura N, )17.7 (T)69.9 (odhunter RJ, et al. )17.7 (The potential and)]TJ
1.675 -1.225 Td
(limitations of cartilage-specific \(V+C\)\(\320\) fibronectin and cartil\
age)Tj
T*
(oligomeric matrix protein as osteoarthritis biomarkers in canine)Tj
T*
(synovial fluid. Osteoarthritis Cartilage 2004;12:818-25.)Tj
-1.675 -1.225 Td
[(8.)-875.1 (Rees-Milton KJ, )17.7 (T)69.9 (erry D, )54.8 (Anastassiades )17.7 (TP)110.8 (. Hyper)17.7 (glycosylation of)]TJ
1.675 -1.225 Td
[(fibronectin by )17.7 (TGF-beta 1-stimulated chondrocytes. Biochem)]TJ
0 Tc T*
(Biophys Res Commun 2004;317:844-50.)Tj
-0.00011 Tc -1.675 -1.225 Td
[(9.)-875.1 (Aldred S, Grant MM, Grif)17.7 (fiths HR. )17.7 (The use of proteomics for the)]TJ
1.675 -1.225 Td
(assessment of clinical samples in research. Clin Biochem)Tj
0 Tc 0 Tw T*
(2004;37:943-52.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.225 Td
[(10.)-875.1 (Xiao Z, Luke BT)73.9 (, Izmirlian G, et al. Serum proteomic profiles)]TJ
2.175 -1.225 Td
[(suggest celecoxib-modulated tar)17.7 (gets and response predictors.)]TJ
T*
(Cancer Res 2004;64:2904-9.)Tj
-2.1381 -1.2 Td
[(1)36.8 (1)-0.1 (.)-875.1 (Couzin J. Clinical trials. Nail biting time for trials of COX-2 drugs.)]TJ
2.1381 -1.2 Td
(Science 2004;306:1673-5.)Tj
-2.175 -1.2 Td
[(12.)-875.1 (Sokolof)17.7 (f L. Osteoarthritis as a remodeling process. J Rheumatol)]TJ
2.175 -1.2 Td
(1987;14: Spec No:7.)Tj
-2.175 -1.2 Td
[(13.)-875.1 (Johnson LC. Joint remodelling as a basis for osteoarthritis. JAMA)]TJ
0 Tc 0 Tw 2.175 -1.2 Td
(1962;141:1237-41.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.2 Td
[(14.)-875.1 (Podworny NV)128.8 (, Kandel RA, Renlund RC, et al. Partial)]TJ
2.175 -1.2 Td
[(chondroprotective ef)17.7 (fect of zoledronate in a rabbit model of)]TJ
0 -1.2 TD
(inflammatory arthritis. J Rheumatol 1999;26:1972-82.)Tj
-2.175 -1.2125 Td
[(15.)-875.1 (Durr HD, Martin H, Pellengahr C, et al. )17.7 (The cause of subchondral)]TJ
2.175 -1.2125 Td
[(bone cysts in osteoarthrosis: a finite element analysis. )54.8 (Acta Orthop)]TJ
0 Tc 0 -1.2125 TD
(Scand 2004;75:554-8.)Tj
-0.00011 Tc -2.175 -1.2125 Td
[(16.)-875.1 (Carbone LD, Nevitt MC, )17.7 (W)39.9 (ildy K, et al. )17.7 (The relationship of)]TJ
2.175 -1.2125 Td
(antiresorptive drug use to structural findings and symptoms of knee)Tj
T*
[(osteoarthritis. )54.8 (Arthritis Rheum 2004;50:3516-25.)]TJ
ET
0 0 0 1 K
53.468 76.5 m
558.468 76.5 l
S
0 0 0 0 k
494.29 69.365 64.178 -15.665 re
f*
BT
0 0 0 1 k
/T1_2 1 Tf
0 Tc 0 Tw 8 0 0 8 545.468 56.4344 Tm
(579)Tj
ET
0 0 0 0 k
53.532 70.5 203 -15.665 re
f*
BT
0 0 0 1 k
/T1_2 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 54.532 57.5695 Tm
(Anastassiades and Rees-Milton: Editorial)Tj
ET
0 0 0 0 k
/GS0 gs
103.585 81.583 407.5 -10.833 re
f*
0.5 w
/GS1 gs
103.585 81.583 407.5 -10.833 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 g
/GS2 gs
/T1_3 8 Tf
108.828 74 Td
(Personal non-commercial use only. The Journal of Rheumatology Copyright\
\251 2005. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_4 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
9 0 obj
<>stream
8;Z\7!HQ(3#kS'\aEMfu6/VqUU$d'4NS>cHilI:e0dZ[W?PHuhPlX++`1jAIUDI,)`SI)GH?*d(pI"c^R8^V4T((de)/ThIn3;s`*#>u@A+ntP5A0t2da
SW#CdPMD7"bmTJHEctQl@)48jcX?'&XRRRed?Ig6h:S^?N"dYoA4;Pe7uE7J5tg
J.#D21J]0Tch]R6AfA_*U7^NA$)aJjO:u8IGV/aqNS'4=o[oN3QG54;$BjSqFIRg^
-0%-@YT@/!NB=mcU0NoK'UR^ZC/C:lp_,u2lrC6RmJmhDpYU~>
endstream
endobj
13 0 obj
[/Indexed/DeviceRGB 255 12 0 R]
endobj
12 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
46 0 obj
<>
endobj
4 0 obj
<>
endobj
32 0 obj
<>
endobj
81 0 obj
<>
endobj
91 0 obj
<>
endobj
33 0 obj
<>
endobj
58 0 obj
<>stream
HtTyPgf.zH JX%jx"Ǡ@0 22ʩh!^bta9<Ϩ1Y}=~TeW{ᘥDTǪ+cԑ&G+,ѐ0;طo[n0vR贇{\'.nj5{&>Woߑ1ngK0JRnH&bq>^Ç'f)cb#hUZ,X*Õ|x*6ߥD+W4*B?ex\ԧ^IZu:W}..la56Ǧ;$,EkI0Ėb*NEEMR,tA%RBz@Uըu͗6%o'dlek{K=A*
TąhHoKM7ȜᏫsٰEj&:0:e+B`~2$i!3VOʔY @".:jN$bcy~]Wp$E?%p>jۈxXa4пărAE)n`B&2m\nt+h}9 H84dF6